XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Balance Sheet Components - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 30, 2024
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]                
Cash and cash equivalents   $ 131,003,000     $ 131,003,000   $ 113,688,000  
Impairment loss   0   $ 0 0      
API and bulk drug product price true-up   12,592,000     12,592,000   50,978,000  
Accrued inventory related cost   8,521,000     8,521,000      
Accrued litigation settlement   28,500,000     28,500,000   28,500,000  
Net unbilled co-development revenue   25,804,000     25,804,000   0  
Litigation settlement receivable   28,500,000     28,500,000   28,500,000  
Restructuring plan, expected reduction to workforce, percentage 75.00%              
Restructuring plan, non-recurring charges   18,554,000   $ 12,606,000 18,554,000 $ 12,606,000    
Cash payments for restructuring         6,100,000      
Accrued restructuring charges   14,200,000     14,200,000      
Short-term investments   0     0   121,898,000  
Long-term investment   0     0      
Eluminex Agreements [Member]                
Schedule of Available-for-sale Securities [Line Items]                
Aggregate consideration received for milestone and upfront payments   4,000,000     4,000,000   4,000,000 $ 8,000,000
AstraZeneca Agreements [Member]                
Schedule of Available-for-sale Securities [Line Items]                
Inventory write-down         12,600,000      
Net unbilled co-development revenue   1,000,000     1,000,000   22,500,000  
Payment to related parties     $ 11,500,000          
Historical co-promotion balances   42,400,000     42,400,000      
Astellas Agreement [Member]                
Schedule of Available-for-sale Securities [Line Items]                
Payment to related parties     $ 35,300,000          
Falikang [Member]                
Schedule of Available-for-sale Securities [Line Items]                
Unbilled receivables   24,800,000     24,800,000      
Foreign subsidiaries [Member]                
Schedule of Available-for-sale Securities [Line Items]                
Cash and cash equivalents   $ 51,000,000     $ 51,000,000   $ 32,200,000